Literature DB >> 8835551

Death attributed to antirheumatic medication in a nationwide series of 1666 patients with rheumatoid arthritis who have died.

R Myllykangas-Luosujärvi1, K Aho, H Isomäki.   

Abstract

OBJECTIVE: Most drugs used in rheumatoid arthritis (RA) can have fatal side effects, but there are no good data on the frequency of such complications. Our study was designed to obtain information on deaths attributable to different antirheumatic drugs.
METHODS: The role of antirheumatic medication as a cause of death was studied in 1666 subjects who died in Finland in 1989 and had been entitled under the nationwide sickness insurance scheme to receive specially reimbursed medication for RA.
RESULTS: Forty-seven deaths were attributed to antirheumatic medication. Thirty deaths were attributed to the use of nonsteroidal antiinflammatory drugs (NSAID) (17 from peptic ulcer, 11 perforation or hemorrhage of the lower intestinal tract, one renal failure, and one bone marrow depression) and 11 deaths to the use of glucocorticoids (2 from perforations of the lower intestinal tract, 5 osteoporotic fractures, 3 septicemias after intraarticular injections and one adrenal insufficiency after abrupt discontinuation of treatment). There were 2 cases of fatal bone marrow depression attributed to methotrexate and 2 to sulfasalazine, one case of lymphoma induced by azathioprine and one hydroxychloroquine intoxication. In spite of widespread use of injectable gold in Finland, there were no deaths attributed to side effects of gold.
CONCLUSION: The data emphasize the frequent occurrence of fatal side effects from NSAID and from glucocorticoids and the relative safety of treatment with gold.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8835551

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  14 in total

1.  [The safety of biologics : a risk-benefit assessment of treating rheumatoid arthritis with biologics based on registry data on mortality].

Authors:  O Sander
Journal:  Z Rheumatol       Date:  2010-11       Impact factor: 1.372

Review 2.  [Development of morbidity and mortality in patients with spondyloarthritis].

Authors:  U Kiltz; J Sieper; J Braun
Journal:  Z Rheumatol       Date:  2011-08       Impact factor: 1.372

Review 3.  Preclinical and clinical development of dexketoprofen.

Authors:  D Mauleón; R Artigas; M L García; G Carganico
Journal:  Drugs       Date:  1996       Impact factor: 9.546

Review 4.  Chronic non-infectious uveitis in the elderly: epidemiology, pathophysiology and management.

Authors:  Rajen Gupta; Philip I Murray
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

5.  [Gold as an alternative in the treatment of RA patients with malignancies].

Authors:  Oliver Sander; Rolf Rau; Matthias Schneider
Journal:  Z Rheumatol       Date:  2016-10       Impact factor: 1.372

6.  Orthopedic surgery among patients with rheumatoid arthritis 1980-2007: a population-based study focused on surgery rates, sex, and mortality.

Authors:  Courtney A Shourt; Cynthia S Crowson; Sherine E Gabriel; Eric L Matteson
Journal:  J Rheumatol       Date:  2012-01-15       Impact factor: 4.666

Review 7.  Thromboembolism with Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis: How Real is the Risk?

Authors:  Ian C Scott; Samantha L Hider; David L Scott
Journal:  Drug Saf       Date:  2018-07       Impact factor: 5.606

8.  Mortality in patients with rheumatoid arthritis treated actively from the time of diagnosis.

Authors:  R Peltomaa; L Paimela; H Kautiainen; M Leirisalo-Repo
Journal:  Ann Rheum Dis       Date:  2002-10       Impact factor: 19.103

9.  Heavy users of non-steroidal anti-inflammatory drugs: a nationwide prescription database study in Finland.

Authors:  Arja Helin-Salmivaara; Timo Klaukka; Risto Huupponen
Journal:  Eur J Clin Pharmacol       Date:  2003-08-21       Impact factor: 2.953

10.  Treatment of rheumatoid arthritis (RA) in India-how and by whom: results from a speciality clinic-use of low-dose methotrexate (MTX) was inexplicably suboptimal.

Authors:  Anand N Malaviya; S B Gogia
Journal:  Clin Rheumatol       Date:  2016-04-28       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.